# Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

> **Open Intelligence Dossier** · First detected: 2026-10-02 16:00 UTC · Category: Business

## Executive Summary
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.


Outlets currently covering the story include BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| simplywall.st | Eli Lilly (LLY) Posts Strong Late Stage Obesity And Diabetes Trial Results | [Source Link](https://news.google.com/rss/articles/CBMi1wFBVV95cUxOOHlJSDhoTEhMOVlPaVR1SG8yQV9XaEE3dkY0aTZMaXRIRlNMYW5scDNIcHF4SDlmT0drU1ZJVGRwMS1WQm1KMmxFMDl4eGppanQxQzBKWjZ5Mmd0V0Z6OVZMZ0twcmVtZ0hfaFIwbWVfdzFBc3BMV21ydDB2aTZBOU1iSHlqTVVJZDVkV1Y1Q0FlOE5EeGNjWWplNGF6MmVJc2Fkc1g2bVI5U0Y0MlAtalk3N0lRczNiTFZzdzNMVlItT1FkSFRvSmstYTVIalltSDlnbHFUd9IB3AFBVV95cUxPSi1IVnpJa29iQzFMNkFVbUpnNjF5aWRFVmJZWlNvRDRMLU9XTW10bDJaUFZMUEh0RjdyOXdCV1B1ZktNel82bGxTUURXN1Zvc1RVVXRvaVpmNmJrSVJLR1NLX3FoaExXSnE2ZXdlY2xNS3IxVlYzQzdYT2R) |
| Medscape | Retatrutide Yields Significant Weight Loss in T2D | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxQRVhUSDF1T09vMHdhX1gzWDdhak5hT0cwYkl2ZkFKbnQtXzJ5YmN0XzBGMUNvejgtYUJkYWFMME1IMG92d2RPdlViVmFCc0F1ci1kRHcwNHhOM041VDZJOGc2aFFVbGJzX1ZwY05jVVphRXRfdzJVeE5RLTltNlYyQUNLekVSU0M5Nk5ZYmZ1OENVZ21RSWVQNlk0Mkk?oc=5) |
| BioPharma Dive | 3 takeaways from a European obesity scientific meeting | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxQSEFNVWZmUVBrMmhOMVV2Z1N4cjFSWmM2V0RZSy1MUDJONkFQejJ4RlJuWDVQblB0T25wVUdxZnBjYUUxWHNzdUZPUEN0cGdycGc0V2dRZEUyY0wxeXdkQXF5aUx1QnBFZzljbG5zTEtkVjRDNHhkX29IeGhTSE5GM0hSZmVyRUpKMUl4NjJ3ZFB2cUdiSzg5bGtmaw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs*